S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:PCVX

Vaxcyte (PCVX) Stock Forecast, Price & News

$50.84
-1.61 (-3.07%)
(As of 09/25/2023 ET)
Compare
Today's Range
$50.78
$52.70
50-Day Range
$46.00
$53.10
52-Week Range
$20.49
$54.97
Volume
1.00 million shs
Average Volume
545,042 shs
Market Capitalization
$4.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.00

Vaxcyte MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
27.9% Upside
$65.00 Price Target
Short Interest
Bearish
8.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Vaxcyte in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$158,460 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.07) to ($3.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

924th out of 962 stocks

Biological Products, Except Diagnostic Industry

156th out of 159 stocks


PCVX stock logo

About Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PCVX Price History

PCVX Stock News Headlines

Vaxcyte (NASDAQ:PCVX) Stock Price Down 2.4%
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
BTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)
Vaxcyte Inc Ordinary Shares
Vaxcyte Stock (NASDAQ:PCVX), Dividends
See More Headlines
Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

PCVX Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PCVX
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$58.00
Forecasted Upside/Downside
+27.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-223,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$12.00 per share

Miscellaneous

Free Float
90,469,000
Market Cap
$4.77 billion
Optionable
Not Optionable
Beta
0.88
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Grant E. Pickering M.B.A. (Age 55)
    Co-Founder, CEO & Director
    Comp: $1.1M
  • Mr. Andrew L. Guggenhime M.B.A. (Age 55)
    Pres & CFO
    Comp: $839.65k
  • Mr. James  Wassil M.B.A.Mr. James Wassil M.B.A. (Age 54)
    M.S., Exec. VP & COO
    Comp: $826.3k
  • Mr. Mikhail Eydelman J.D. (Age 42)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $793.22k
  • Mr. Paul W. Sauer M.B.A. (Age 62)
    MBA, Sr. VP of Process Devel. & Manufacturing
    Comp: $608.96k
  • Dr. Ashish Khanna M.B.A. (Age 51)
    Ph.D., Co-Founder
  • Dr. Jeff Fairman Ph.D. (Age 59)
    Co-Founder & VP of Research
  • Ms. Elvia Cowan (Age 50)
    Sr. VP of Fin. & Principal Accounting Officer
  • Ms. Janet Graesser
    VP of Corp. Communications & Investor Relations
  • Karen Alderete
    Exec. Director of HR













PCVX Stock - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings
or view top-rated stocks.

What is Vaxcyte's stock price forecast for 2023?

6 brokerages have issued 1 year target prices for Vaxcyte's shares. Their PCVX share price forecasts range from $58.00 to $70.00. On average, they anticipate the company's stock price to reach $65.00 in the next year. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for PCVX
or view top-rated stocks among Wall Street analysts.

How have PCVX shares performed in 2023?

Vaxcyte's stock was trading at $47.95 at the beginning of the year. Since then, PCVX shares have increased by 6.0% and is now trading at $50.84.
View the best growth stocks for 2023 here
.

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our PCVX earnings forecast
.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.04.

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).

When did Vaxcyte IPO?

(PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

What is Vaxcyte's stock symbol?

Vaxcyte trades on the NASDAQ under the ticker symbol "PCVX."

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (8.41%), BlackRock Inc. (7.53%), Capital Research Global Investors (3.58%), State Street Corp (3.37%), Alliancebernstein L.P. (2.01%) and Braidwell LP (1.84%). Insiders that own company stock include Andrew Guggenhime, Grant Pickering, Group Holdings (Sbs) Advis Tpg, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Paul Sauer, Ra Capital Healthcare Fund Lp, Ra Capital Management, LP and Robert Lorne Hopfner.
View institutional ownership trends
.

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxcyte's stock price today?

One share of PCVX stock can currently be purchased for approximately $50.84.

How much money does Vaxcyte make?

Vaxcyte (NASDAQ:PCVX) has a market capitalization of $4.77 billion. The company earns $-223,490,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis.

How many employees does Vaxcyte have?

The company employs 158 workers across the globe.

How can I contact Vaxcyte?

Vaxcyte's mailing address is 353 HATCH DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.vaxcyte.com. The company can be reached via phone at 650-837-0111 or via email at investors@vaxcyte.com.

This page (NASDAQ:PCVX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -